Skip to main content
Figure 1 | Arthritis Research & Therapy

Figure 1

From: Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation

Figure 1

Clinical response to treatment is independent of trough serum adalimumab levels. Trough serum adalimumab levels at the end of treatment (2 weeks after the last injection) were not different between patients treated with 12 or 24 weeks of adalimumab (A) or between responders and nonresponders (B) Median (interquartile range). Also, there was no correlation between these drug levels and clinical disease activity parameters such as patient’s global assessment of disease activity measured on a 100-mm visual analogue scale (VAS) (C) or C-reactive protein (CRP) level (D).

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us